Trial Profile
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis With Severe Thrombocytopenia (Platelet Count <50,000/μL)(PACIFICA)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Pacritinib (Primary) ; Corticosteroids; Danazol; Hydrocortisone sodium succinate; Hydrocortisone sodium succinate; Hydroxycarbamide; Lenalidomide; Methylprednisolone; Prednisone; Ruxolitinib; Thalidomide
- Indications Myelofibrosis
- Focus Registrational; Therapeutic Use
- Acronyms PACIFICA
- Sponsors CTI BioPharma
- 13 Dec 2022 Trial design presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 03 Nov 2022 According to a CTI BioPharma media release, data from the study will be presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.
- 09 Aug 2022 Planned number of patients changed from 348 to 399.